Why You Should Consider Buying ResMed Stock After Its First

ResMed (RMD) has issued its first annual guidance, targeting $5.75B-$5.85B in FY27 revenue and $12.00-$12.25 non-GAAP EPS, implying a 12-14% core EPS growth when temporary headwinds are excluded. While street analysts are cautious and have trimmed price targets, TIKR's model values ResMed stock at $346 by mid-2031, suggesting a 54% total return. This indicates a disconnect between analyst sentiment and the company's underlying growth story, particularly as temporary drags resolve.